T 2627/17 of 25.01.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T262717.20220125
- Date of decision
- 25 January 2022
- Case number
- T 2627/17
- Petition for review of
- -
- Application number
- 14155086.3
- IPC class
- C07D 249/18C07D 401/06C07D 417/10C07D 413/10A61K 31/4192C07D 231/56A61K 31/416C07D 401/12A61P 35/00C07D 409/06C07D 403/10
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Estrogen receptor modulators and uses thereof
- Applicant name
- Seragon Pharmaceuticals, Inc.
- Opponent name
- Furo Ventures B.V.
- Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56European Patent Convention Art 83
- Keywords
- Sufficiency of disclosure
Inventive step - Catchword
- -
- Citing cases
- T 1057/22
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent as amended on the basis of
- claims 1-15 of auxiliary request 5 submitted with the letter dated 19 November 2021,
- amended page 123 of the granted patent submitted with the letter dated 15 September 2017, and
- a description to be further adapted thereto, if necessary.